Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (1042)	7/2/1998 11:52:00 AM
From: Stephen How	Read Replies (1) \| Respond to of 1432

What's your point? Jim, My last posts says that even Biotime doesn't think that added electrolytes solve the limitations of hetastarch. They think that albumin + electrolytes + buffer + [another optional HES or Dextran] is a better solution than Hextend&reg. I'm posting from the patents, because I want to see what the advantages and science of Hextend&reg really are. I've found that Biotime seems to indicate a maximum 1.5 L/day dosage for plasma expansion. They also say that using albumin is better than just using hetastarch in their invention. What's the point of your question? <Steve awaits the personal attack.> Steve btim.dyn.ml.org